**Core Concept**
The lipooxygenase pathway is a metabolic pathway that converts arachidonic acid into leukotrienes, which play a crucial role in inflammatory responses. This pathway is distinct from the cyclooxygenase pathway, which produces prostaglandins and thromboxanes.

**Why the Correct Answer is Right**
Leukotrienes, particularly LTB4, LTC4, LTD4, and LTE4, are potent mediators of inflammation. They promote vasoconstriction by causing smooth muscle contraction, leading to increased vascular resistance. Additionally, leukotrienes increase vascular permeability by inducing the contraction of endothelial cells, thereby facilitating the movement of leukocytes and fluid from the bloodstream into the interstitial space.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is not relevant to the lipooxygenase pathway or the effects of leukotrienes on vascular tone and permeability.
**Option B:** This option refers to the cyclooxygenase pathway, which is distinct from the lipooxygenase pathway. Prostaglandins and thromboxanes have different effects on vascular tone and permeability.
**Option C:** This option is a type of leukotriene, but it is not the primary mediator of vasoconstriction and increased vascular permeability in the context of the lipooxygenase pathway.

**Clinical Pearl / High-Yield Fact**
Leukotriene modifiers, such as montelukast, are used in the management of asthma and allergic rhinitis by inhibiting the action of leukotrienes on their receptors, thereby reducing inflammation and airway constriction.

**Correct Answer:** C. Leukotriene D4 (LTD4)